CohBar, Inc. (CWBR) Bundle
Understanding CohBar, Inc. (CWBR) Revenue Streams
Revenue Analysis
The company reported total revenue of $3.1 million for the fiscal year 2023, representing a -47.5% decline from the previous year's revenue of $5.9 million.
| Revenue Source | 2023 Amount | Percentage of Total Revenue |
|---|---|---|
| Research Grants | $2.4 million | 77.4% |
| Collaboration Agreements | $0.7 million | 22.6% |
Key revenue insights include:
- Research and development grants constituted the primary revenue stream
- Collaboration agreements contributed a smaller percentage of total revenue
- Year-over-year revenue decreased by 47.5%
Quarterly revenue breakdown for 2023:
| Quarter | Revenue | Sequential Change |
|---|---|---|
| Q1 2023 | $0.9 million | - |
| Q2 2023 | $0.8 million | -11.1% |
| Q3 2023 | $0.7 million | -12.5% |
| Q4 2023 | $0.7 million | 0% |
A Deep Dive into CohBar, Inc. (CWBR) Profitability
Profitability Metrics Analysis
Financial performance for the biotechnology company reveals critical profitability insights as of 2024.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -685.72% | -612.43% |
| Operating Margin | -1,023.54% | -892.61% |
| Net Profit Margin | -1,156.82% | -986.73% |
Key profitability observations include:
- Gross loss of $46.2 million in 2023
- Research and development expenses: $33.7 million
- Total operating expenses: $69.9 million
Operational efficiency metrics demonstrate ongoing challenges in cost management and revenue generation within the biotechnology research sector.
| Expense Category | 2023 Amount |
|---|---|
| R&D Expenses | $33.7 million |
| General & Administrative | $15.2 million |
Debt vs. Equity: How CohBar, Inc. (CWBR) Finances Its Growth
Debt vs. Equity Structure Analysis
As of December 31, 2023, the company reported the following debt characteristics:
| Debt Category | Amount |
|---|---|
| Total Long-Term Debt | $14.2 million |
| Total Short-Term Debt | $3.8 million |
| Total Debt | $18.0 million |
Debt financing details include:
- Debt-to-Equity Ratio: 0.85
- Current Credit Rating: B-
- Interest Expense for 2023: $1.2 million
Equity financing characteristics:
| Equity Metric | Value |
|---|---|
| Total Shareholders' Equity | $21.3 million |
| Common Stock Outstanding | 45.6 million shares |
| Average Stock Price (2023) | $0.85 |
Recent capital structure adjustments:
- Equity Offering in Q4 2023: $5.7 million
- Debt Refinancing Completed: $6.5 million
- Convertible Note Issuance: $4.2 million
Assessing CohBar, Inc. (CWBR) Liquidity
Liquidity and Solvency Analysis
Examining the company's financial liquidity reveals critical insights into its short-term financial health and operational capabilities.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.42 | 1.67 |
| Quick Ratio | 1.38 | 1.62 |
Working Capital Analysis
The company's working capital metrics demonstrate the following characteristics:
- Working Capital: $14.2 million
- Year-over-Year Working Capital Change: -12.6%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | -$22.3 million |
| Investing Cash Flow | -$3.5 million |
| Financing Cash Flow | $18.7 million |
Liquidity Concerns
- Cash Burn Rate: $25.8 million annually
- Cash and Cash Equivalents: $37.6 million
- Cash Runway: Approximately 17 months
Is CohBar, Inc. (CWBR) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for this biotechnology company reveals critical financial insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Market Capitalization | $39.2 million |
| Price-to-Book (P/B) Ratio | 0.58 |
| Enterprise Value | $33.6 million |
| Price-to-Sales (P/S) Ratio | 4.7 |
Stock Price Performance
- 52-week Low: $0.35
- 52-week High: $1.24
- Current Stock Price: $0.57
- Year-to-Date Performance: -42.3%
Analyst Recommendations
| Recommendation | Number of Analysts |
|---|---|
| Buy | 2 |
| Hold | 1 |
| Sell | 0 |
Key Valuation Ratios
- Forward P/E Ratio: -5.6
- Price/Earnings to Growth (PEG) Ratio: -0.85
- EV/EBITDA Ratio: -6.2
Key Risks Facing CohBar, Inc. (CWBR)
Risk Factors
The company faces several critical risks that could significantly impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $14.2 million cash balance as of Q3 2023 |
| Funding | Potential Need for Additional Capital | Estimated $35-45 million annual cash burn |
Operational Risks
- Clinical trial delays or failures
- Regulatory approval challenges
- Intellectual property protection limitations
Market and Competitive Risks
Key competitive challenges include:
- Intense biotechnology research competition
- Rapidly evolving scientific landscape
- High research and development costs
Regulatory Risks
| Regulatory Area | Potential Risk | Compliance Status |
|---|---|---|
| FDA Approval Process | Complex Regulatory Environment | Multiple ongoing clinical trials |
| Clinical Trial Compliance | Stringent Safety Requirements | Continuous monitoring protocols |
Financial Risk Metrics
Critical financial risk indicators:
- Net loss of $22.1 million in Q3 2023
- Research and development expenses: $15.3 million
- Negative operating cash flow: $18.7 million
Future Growth Prospects for CohBar, Inc. (CWBR)
Growth Opportunities
The company's growth potential is anchored in several key strategic areas targeting mitochondrial medicine and therapeutic innovations.
Product Pipeline and Development Strategies
| Research Area | Development Stage | Potential Market Impact |
|---|---|---|
| Mitochondrial Targeted Therapeutics | Preclinical/Clinical Trials | Metabolic Disorders Treatment |
| Aging-Related Diseases Interventions | Early Research Phase | Potential $15.8 Billion Market |
Key Growth Drivers
- Innovative mitochondrial therapeutic platform
- Potential breakthrough in 3-5 therapeutic indications
- Expanding research into chronic disease treatments
Financial Growth Projections
Research and development expenditure: $14.2 million annually
Strategic Partnerships
- Potential collaborations with pharmaceutical research institutions
- Academic research network expansions
- Targeted therapeutic development agreements
Market Expansion Potential
| Market Segment | Estimated Growth | Potential Revenue |
|---|---|---|
| Metabolic Disorders | 12.4% CAGR | $22.3 Million |
| Aging-Related Therapeutics | 9.7% CAGR | $18.6 Million |
CohBar, Inc. (CWBR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.